Background: Medullary thyroid cancer (MTC) is a rare cancer that has historically been managed by endocrinologists. In 2011, the first of several multi-targeted tyrosine kinase inhibitors was approved as treatment for MTC. These drugs have changed the management of MTC to teams that include oncologists and oncology nurses.
Objectives: This article illustrates MTC diagnostics, surveillance, management of adverse drug reactions, and disease progression through a case study.
Methods: An overview of MTC is offered, followed by an in-depth case study that examines MTC from the patient’s perspective.
Findings: Oncology nurses can influence patient outcomes through the provision of patient education, support, and management of disease and treatment complications.